Clinical Trial

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 120 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker. CANYON and GRAND CANYON are fully enrolled.
Protocol Amendment History 41 amendments
This ClinicalTrials.gov record has been amended 41 times since 2022-03-14; most recent amendment 2026-05-18.
Status change: Recruiting → Active, Not Recruiting 2025-02-04
Status change: Not Yet Recruiting → Recruiting 2022-07-11
Trial Details
NCT Number NCT05291091
Lead Sponsor Edgewise Therapeutics, Inc.
Collaborators: Medpace, Inc., ImagingNMD, SYSNAV
Conditions Becker Muscular Dystrophy
Enrollment 244 participants
Start Date 2022-11-10
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-31